The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...

High dose and low dose AMT-130 demonstrated an 80% and 30% slowing of disease progression vs external control, respectively. The Food and Drug Administration has granted Breakthrough Therapy ...

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.

Shares of Praxis Precision Medicines (NASDAQ: PRAX) leaped on Monday after the clinical-stage biopharmaceutical company ...

Novartis’ ITVISMA, approved a month ago by the US FDA, used at Sheikh Khalifa Medical City under the supervision of the ...

A single jab of a breakthrough gene therapy could reverse hearing loss in people within weeks, according to new research. The cutting-edge therapy improved hearing in children and adults with ...

Phase 2 trial results showed an improvement in MASH with no worsening of fibrosis in all treatment groups compared with placebo. The Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

There is no cure for the rare disease Hereditary Spastic Paraplegia (HSP), but researchers from Drexel University’s College ...

Cancer has long remained a leading cause of death worldwide and in Hong Kong, accounting for 30% of all disease-related ...

At Breakthrough Therapy and Resources, we provide clinical support for individuals experiencing distress due to various life experiences. Utilizing a range of therapeutic interventions, we offer ...